This invention provides an ActRII inhibitor for use in a method for treating chronic kidney disease-mineral and bone disorder (CKD-MBD) in a subject, wherein said ActRII inhibitor is a polypeptide comprising an amino acid sequence selected from the group disclosed in the application.